tbuckley/cabot-search huggingface dataset:
STATE BOARD STATISTICS FOR 1926
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gene Expression Profiling of Facilitated L-LTP in VP16-CREB Mice Reveals that BDNF Is Critical for the Maintenance of LTP and Its Synaptic Capture
Authors: Angel Barco, Susan Patterson, Juan M. Alarcon, Petra Gromova, Manuel Mata-Roig, Alexei Morozov, Eric R. Kandel
Journal: Neuron (2007)
Gangliosides in neurological diseases.
Authors: A G Garcia, J Berciano, J F Horga, S Lopez-Pousa, J M Martinez-Lage, J Matias-Guiu
Journal: BMJ (1993)

antibodies and in vitro indices of inherent toxicity of sera in patients with Guillain-Barr& syndrome.6We see no scientific justification for the statement about the immunogenicity of gangliosides, nor do we find any direct evidence to support the conten- tion that naturally occurring antibodies to mono- sialoganglioside are pathogenic.Thus, we feel that the recommendation to suspend human trials is erroneous, unjustified, and devoid of scientific merit.
AB0183 Plasma Levels of PF-4VAR/CXCL4L1, A Non Allelic Variant of Platelet Factor-4 (PF-4/CXCL4), are Elevated in Patients with Antiphospholipid Syndrome (APS)
Authors: M.P. Sikara, M.D. Patsouras, A.G. Tzioufas, P.G. Vlachoyiannopoulos
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Platelet derived chemokines, such as PF-4 and its nonallelic variant PF-4var, are implicated in several aspects of thrombosis and inflammation. Previous study from our group demonstrates a novel interaction between β2-glycoprotein I (β2GPI) and PF-4 or PF-4var. <h3>Objectives</h3> To determine PF-4var plasma levels and platelet PF-4var expression (RNA level) in patients with APS and evaluate the correlation with clinical and laboratory parameters of the disease. <h3>Methods</h3> From 90 patients, who fulfill the revised diagnostic criteria for APS, blood samples were taken and separate samples of serum, plasma and platelets were isolated. A healthy control (n=55) and a disease control group (SLE, n=30) were included in the study. Plasma levels of PF-4var were determined using an ELISA, which absolutely discriminates PF-4var from PF-4. Platelet PF-4var and PF4 RNA levels were determined in RNA isolated from platelet preparations using RT-PCR. <h3>Results</h3> APS patients showed higher levels of plasma PF-4var compared to healthy individuals or SLE patients (APS: median 137.4 pg/ml; intarquartile range 65.69-219.2 pg/ml versus HD: 60.52 [36.04-97.12] pg/ml, p&lt;0.0001 or SLE: 51.20 [16.37-172.9] pg/ml, p=0.0027). In addition, RT-PCR revealed significantly higher PF-4var expression in platelets derived from APS patients comparing to healthy donors or lupus patients (2<sup>-ΔΔCT</sup>: APS: 1.461; [0.6743-2.796] versus HD: 0.815 [0.4260-1.132], p=0.0020 or SLE: 0.7505 [0.4790-1.136] p=0.0017). PF-4var levels were significantly elevated in patients with primary APS than those with APS secondary to SLE [p=0.0086]. Regarding the clinical presentation of the disease, patients who experienced thrombotic events versus pregnancy morbidity or arterial versus venous thrombotic events do not show statistically significant difference in PF-4var levels. A positive correlation was revealed between thrombocytopenia and elongation of aPTT with the higher PF-4var levels. <h3>Conclusions</h3> Preliminary results suggest that higher PF-4var levels are present in plasma of APS patients and especially in those with PAPS and these are associated with laboratory characteristics indicative for higher risk of thrombotic complications. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3696
Error in SD Value in Table
Journal: JAMA Pediatrics (2015)

Ronald J. Sigal, MD, MPH; Angela S. Alberga, PhD; Gary S. Goldfield, PhD; Denis Prud’homme, MD, MSc; Stasia Hadjiyannakis, MD; Réjeanne Gougeon, PhD; Penny Phillips, MA; Heather Tulloch, PhD; Janine Malcolm, MD; Steve Doucette, MSc; George A. Wells, PhD; Jinhui Ma, PhD; Glen P. Kenny, PhD
Recent developments in legal aspects of accreditation
Authors: M. H. Cardozo
Journal: JAMA (1970)

In order to appreciate the recent developments in the legal aspects of accreditation in the United States, it is important to bear in mind the legal basis of the accreditation of higher education in this country. In many areas of elementary and secondary education and professional practice, most of the same considerations apply. The subject was thoroughly treated in a student comment in the<i>Cornell Law Quarterly</i>in 1966. The most significant aspect of accreditation in the United States is its "voluntary" character. This means that it arises out of the spontaneous action of private individuals and organizations, rather than from some governmental action. If you want to operate a bus system in a city, a railroad across state lines, or an international airline, you can find elaborate prescriptions in governmental statutes and regulations describing what you have to do before you can start and how you must operate when
Measuring Vitality
Authors: C Wood, M E Magnello, T Jewell
Journal: Journal of the Royal Society of Medicine (1990)

Subjective perceptions of mental and physical energy were measured by the use of visual analogue scales (VAS) over the course of a week in a group of normal volunteers. These variables were found to correlate, highly both with one another and with assessments of vigour and fatigue measured with a standard adjectival format. In addition, high correlations were found with a measure of positive affect. These five variables also displayed characteristic patterns of diurnal variation. Physical and mental energy, vigour and positive affect were highest in the morning, falling progressively and significantly over the day. In contrast, fatigue showed the opposite pattern. Extraversion showed positive correlations with physical and mental energy, vigour and positive affect, and negative correlations with fatigue and negative affect, most being significant (P&lt;0.05). Conversely, neuroticism showed a negative correlation with the first four energy variables but was positively related to fatigue and negative affect, most correlations again being significant. Physical and mental energy, vigour and positive affect also showed a positive correlation (P&lt;0.01) with a measure of happiness. It is concluded that VAS-derived ratings of physical and mental energy are reliable indicators of self-perceived vigour and fatigue. They are easy to record and show sufficient short-term stability to be used in more extensive studies both of well-being and of its physiological correlates.
MUSEUM FATIGUE
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Stomach
Authors: Bernard Sigel
Journal: JAMA (1993)

This book is a collection of review articles dealing with basic and clinical subjects related to the stomach. The approach is multidisciplinary with the participation of authors with backgrounds in anatomy, pathology, cell biology, epidemiology, physiology, biochemistry, pharmacology, internal medicine, and surgery. Although there is limited cross-referencing, the review articles are exsentially independent of each other. The general format emphasizes the authors' own work or experience and summarizes, usually quite thoroughly, the literature in the field. The references are extensive, pertinent, and current. The illustrative material is sufficient and clear. Recent advances, which are presented in appropriate detail, emphasize<i>Helicobacter pylori</i>infections, H<sub>2</sub>antagonists, proton pump inhibitors, and endoscopic techniques to control bleeding. Older knowledge is updated to comply with current information. The clinical chapters generally stress medical over surgical management. The inability of the book to provide more detailed consideration of surgical management of some gastric or gastric-related
MISCELLANEA MEDICA
Authors: Phil Gunby
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Royal Commission on Medical Education.
Authors: G Nossal, K Russell, John Eccles, Lord Platt, Edward Coliingwood, Brian Windeyer, Peter Medawar, A Lowdon, J Ellis, Jsephine Miss, G Barnes, Mr Carstairs, Andrew Dizon, Mr Kay, J Parry, R Titmuss, B Wright, P Young, J Barber, Eq Mrs, C Chilver, G Fleming
Journal: BMJ (1968)

the present director of the Institute, the cellular immuno- logy unit is devoted to a study of autoimmune diseases in special strains of mice.The cancer research unit, directed by the Carden Fellow of the Anti-cancer Council of Victoria, Dr. Donald Metcalf, ni engaged in a continuous study of leukaemia with special reference to lymphatic leukaemia.A main aspect of the work is the investigation of various factors in the serum of human beings and animals with leukaemia which permit the growth of bone-marrow cells in vitro.
Complications in Surgery and Trauma
Authors: R. Dale Liechty
Journal: JAMA (1985)

Surgeons exist in a world of complications. For example, we plan most operative treatment to prevent or treat complications—from gallstones, hernias, tumors, and ulcers. Then we have to treat the secondary complications—from the treatments. When a book appears that offers us help with complications, we welcome it; readers should heartily accept this one. In 63 chapters, the authors take us through the common and uncommon complications of wounds, shock, coagulation, nutrition, antibiotics, anesthesia, and the main sections, the organ systems. The final chapter, "A Synopsis of Surgical Complications," summarizing the text, lists common operative procedures and their morbidity and mortality rates. For completeness, the editors included the main subspecialties, even renal transplantation. During a hysterectomy did you injure a ureter? The urologic chapter will tell you how to repair it. Did you operate for appendicitis and find Crohn's disease of the ileum? You will find the solution: remove the appendix
Abstract 4915: Optimal frequency of follow up scans on systemictherapy for advanced malignancies
Authors: David J. Stewart, Blair Macdonald, Sasha Van Katwyk, Arif Awan, Kednapa Thavorn
Journal: Cancer Research (2019)

Abstract Background: Frequency of follow-up scans is specified in trials but there is little evidence to guide optimal frequency in standard therapy. Progression-free survival (PFS) generally follows first order kinetics and PFS half-lives (calculated by nonlinear regression analysis of more than 300 published PFS curves) correlated strongly with PFS medians (Stewart, AACR 2018). Method: We used the Excel formula EXP(-tn*0.693/t1/2) to calculate proportion of residual patients remaining progression-free at different time intervals, where tn is the potential time of follow-up scans (eg, every 3 weeks, 6 weeks, etc), * indicates multiplication, 0.693 is the natural logarithm of 2, and t1/2 is the PFS half-life in weeks. Results: Proportion of remaining patients expected to still remain progression-free at each subsequent scan varied with time interval between scans and with PFS half-life for the individual regimen. For example, with a PFS half-life of 4 months (17.3 weeks) and scans repeated every 6 weeks, 21% of the patients would have progressed by the first scan, 21% of the remaining patients would have progressed by the second scan at 12 weeks, etc. With PFS half-lives of 2, 4, 6, 12 and 20 months (for example), the proportion of remaining patients progressing by the time of each subsequent follow up scan if the scans were repeated every 3 weeks would be 21%, 11%, 8%, 4% and 2%, respectively, while with scans repeated every 6 weeks the proportion progressing would be 38%, 21%, 15%, 8% and 5%, by 12 weeks it would be 62%, 38%, 27%, 15% and 9%, and by 15 weeks it would be 70%, 45%, 33%, 18% and 11%, respectively. Conclusions: For therapies with short PFS half-lives, scanning every 6 weeks may not be often enough, while with long PFS half-lives, less frequent scans may be warranted. We plan analyses to estimate economic implications of varying scan frequency based on PFS half-life, drug and toxicity costs, opportunity costs (where other effective therapies might be offered if progression is detected), etc. We will also assess how this approach might be adapted for PFS curves that follow exponential 2-phase decay due to presence of distinct good vs poor prognosis subgroups, and we are in the process of using published PFS curves to assess the PFS half-lives for multiple different cancer therapies. Citation Format: David J. Stewart, Blair Macdonald, Sasha Van Katwyk, Arif Awan, Kednapa Thavorn. Optimal frequency of follow up scans on systemictherapy for advanced malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4915.
Infection, Immunity and Serum Therapy. In Relation to the Infectious Diseases which Attack Man; with Considerations of the Allied Subjects of Agglutination, Precipitation, Hemolysis, etc.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum: Dynamic DNA methylation programs persistent adverse effects of early-life stress
Authors: Chris Murgatroyd, Alexandre V Patchev, Yonghe Wu, Vincenzo Micale, Yvonne Bockmühl, Dieter Fischer, Florian Holsboer, Carsten T Wotjak, Osborne F X Almeida, Dietmar Spengler
Journal: Nature Neuroscience (2010)
The impact of time to adjuvant chemotherapy (AC) on survival in colorectal cancer (CRC): A systematic review and meta-analysis.
Authors: M. Raphael, J. J. Biagi, W. J. Mackillop, W. Kong, W. D. King, C. M. Booth
Journal: Journal of Clinical Oncology (2011)

6125 Background: The optimal timing from CRC surgery to initiation of AC is unknown. We report a systematic review and meta-analysis to determine the relationship between time to adjuvant chemotherapy (TTAC) and survival. Methods: A systematic review of literature was completed to identify studies that described the relationship between TTAC and survival. Studies were only included if the distribution of relevant prognostic factors was adequately described, and either comparative groups were balanced or results adjusted for the prognostic factors. Hazard ratio (HR) and TTAC for overall survival (OS) and disease free survival (DFS) from each study were converted to a regression coefficient (β) and standard error (SE) corresponding to a continuous representation per 4 weeks of TTAC. The adjusted β from individual studies were combined using a fixed-effect model. Inverse-variance (1/SE2) was used to weight individual studies. The possible effect of publication bias was investigated using the trim and fill approach. Results: We identified 9 eligible studies involving 14,357 patients (4 published articles, 5 abstracts). Two studies were randomized trials and 7 were cohort studies. Six studies reported TTAC as a binary variable and 3 reported TTAC as ≥3 categories. An estimate of HR for OS was derived from all 9 studies and estimate for DFS was derived from 5 studies. Meta-analysis demonstrated that a 4-week increase in TTAC was associated with an OS HR of 1.12 (95% CI 1.09-1.15), and DFS HR of 1.15 (95% CI 1.11-1.20). The analysis showed no significant heterogeneity among studies. These TTAC associations remained significant after analysis for potential publication bias, and when the analysis was repeated excluding the studies of largest weight. Conclusions: This study demonstrates a 12% increase in the risk of death for each 4 week of delay in the start of AC for CRC. These findings indicate the need for clinicians and health systems managers to monitor TTAC for quality assurance purposes, and to take the steps necessary to keep TTAC as short as reasonably achievable. In addition, our results suggest there may be some benefit to AC after a 3 month TTAC delay.
Prevalence of Chronic Migraine Headaches— United States, 1980-1989
Journal: JAMA (1991)

Migraine headaches, which are characterized by painful, disabling, and recurring symptoms, have no known cause, treatment, or cure. Quality population-based data are needed to improve epidemiologic understanding of chronic migraine headaches. This report uses data from the National Health Interview Survey (NHIS) to describe the prevalence of recent trends in the occurrence of chronic migraine headaches in the United States from 1980 through 1989.
THROMBOPLASTIC PRODUCTS
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
J Neuropathology &amp;amp; Exp Neurology, Baltimore
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal